These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 18261624

  • 1. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V, Bellone G, Battaglia E, Rossi E, Carbone A, Prati A, Verna C, Niola P, Morelli A, Grassini M, Bassotti G.
    Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
    [Abstract] [Full Text] [Related]

  • 2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [Abstract] [Full Text] [Related]

  • 3. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA, Remotti H, Baergen RN, Altorki NK.
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [Abstract] [Full Text] [Related]

  • 4. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L, Goldman H, Odze RD.
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [Abstract] [Full Text] [Related]

  • 5. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D, Fléjou JF.
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [Abstract] [Full Text] [Related]

  • 6. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid BJ, Odze RD.
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [Abstract] [Full Text] [Related]

  • 7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN.
    Cancer Res; 2005 Apr 15; 65(8):3146-54. PubMed ID: 15833844
    [Abstract] [Full Text] [Related]

  • 8. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
    Hermann B, Li Y, Ray MB, Wo JM, Martin RC.
    Arch Surg; 2005 Dec 15; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
    [Abstract] [Full Text] [Related]

  • 9. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.
    Am J Gastroenterol; 2009 Nov 15; 104(11):2673-80. PubMed ID: 19638963
    [Abstract] [Full Text] [Related]

  • 10. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
    Bektas N, Donner A, Wirtz C, Heep H, Gabbert HE, Sarbia M.
    Am J Clin Pathol; 2000 Dec 15; 114(6):890-5. PubMed ID: 11338478
    [Abstract] [Full Text] [Related]

  • 11. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.
    Sarbia M, Bektas N, Müller W, Heep H, Borchard F, Gabbert HE.
    Cancer; 1999 Dec 15; 86(12):2597-601. PubMed ID: 10594854
    [Abstract] [Full Text] [Related]

  • 12. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.
    Cancer Epidemiol Biomarkers Prev; 2008 Jun 15; 17(6):1380-5. PubMed ID: 18559552
    [Abstract] [Full Text] [Related]

  • 13. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
    Morales CP, Lee EL, Shay JW.
    Cancer; 1998 Aug 15; 83(4):652-9. PubMed ID: 9708927
    [Abstract] [Full Text] [Related]

  • 14. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J, Ross AS, Konda VJ, Lin S, Noffsinger A, Hart J, Waxman I.
    Gastrointest Endosc; 2009 Sep 15; 70(3):417-21. PubMed ID: 19555948
    [Abstract] [Full Text] [Related]

  • 15. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R, Odze RD.
    Am J Surg Pathol; 2006 Jul 15; 30(7):871-7. PubMed ID: 16819330
    [Abstract] [Full Text] [Related]

  • 16. Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells.
    Edmiston JS, Yeudall WA, Chung TD, Lebman DA.
    Cancer Res; 2005 Jun 01; 65(11):4782-8. PubMed ID: 15930298
    [Abstract] [Full Text] [Related]

  • 17. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V, Rossi E, Zambelli C, Galletti A, Cestari R, Missale G, Casa DD, Bassotti G.
    Dig Liver Dis; 2007 Apr 01; 39(4):305-11. PubMed ID: 17307036
    [Abstract] [Full Text] [Related]

  • 18. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A, Dumonceau JM, Bruttin F, Vonlaufen A, Morard I, Spahr L, Rubbia-Brandt L, Frossard JL, Dinjens WN, Rabinovitch PS, Hadengue A.
    Mol Cancer; 2006 Oct 20; 5():48. PubMed ID: 17054793
    [Abstract] [Full Text] [Related]

  • 19. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia.
    Younes M, Ertan A, Lechago LV, Somoano J, Lechago J.
    Cancer Epidemiol Biomarkers Prev; 1997 May 20; 6(5):303-5. PubMed ID: 9149888
    [Abstract] [Full Text] [Related]

  • 20. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
    Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG.
    Mol Carcinog; 1998 Jul 20; 22(3):182-9. PubMed ID: 9688144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.